Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia

Genes Chromosomes and Cancer

Volumn 51, Issue 11, 2012, Pages 1045-1053

  Krumbholz, Manuela ^a   Karl, Matthias ^a   Tauer, Josephine T ^b   Thiede, Christian ^b   Rascher, Wolfgang ^a   Suttorp, Meinolf ^b   Metzler, Markus ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA;

ADOLESCENT; ADULT; ARTICLE; BCR ABL1 FUSION GENE; CHILD; CHRONIC MYELOID LEUKEMIA; DNA SEQUENCE; DNA STRAND BREAKAGE; FEMALE; FUSION GENE; GENE SEQUENCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME BREAKPOINTS; COHORT STUDIES; DNA, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INFANT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84865980394     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21989     Document Type: Article

References (39)

1. Bartley PA, Martin-Harris MH, Budgen BJ, Ross DM, Morley AA. 2010a. Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia. Br J Haematol 149: 231-236.
2. Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S, Hughes TP, Morley AA. 2010b. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol 32: e222-e228.
3. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann R. 2005. Gender aspects in chronic myeloid leukemia: Long-term results from randomized studies. Leukemia 19: 984-989.
4. Bornhauser M, Mohr B, Oelschlaegel U, Bornhauser P, Jacki S, Ehninger G, Thiede C. 2007. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 21: 1824-1826.
5. Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D. 2007. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 110: 979-985.
6. Burmeister T, Groger D, Kuhn A, Hoelzer D, Thiel E, Reinhardt R. 2011. Fine structure of translocation breakpoints within the major breakpoint region in BCR-ABL1-positive leukemias. DNA Repair (Amst) 10: 1131-1137.
7. Busch K, Keller T, Fuchs U, Yeh RF, Harbott J, Klose I, Wiemels J, Novosel A, Reiter A, Borkhardt A. 2007. Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14) translocations in sporadic Burkitt-lymphoma. Leukemia 21: 1739-1751.
8. Felix CA, Hosler MR, Slater DJ, Parker RI, Masterson M, Whitlock JA, Rebbeck TR, Nowell PC, Lange BJ. 1998. MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children. J Pediatr Hematol Oncol 20: 299-308.
9. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC. 2008. Long-term imatinib therapy promotes bone formation in CML patients. Blood 111: 2538-2547.
10. Gollin SM. 2007. Mechanisms leading to nonrandom, nonhomologous chromosomal translocations in leukemia. Semin Cancer Biol 17: 74-79.
11. Greaves MF, Wiemels J. 2003. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 3: 639-649.
12. Jeffs AR, Benjes SM, Smith TL, Sowerby SJ, Morris CM. 1998. The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia. Hum Mol Genet 7: 767-776.
13. Jones LK, Neat MJ, van Delft FW, Mitchell MP, Adamaki M, Stoneham SJ, Patel N, Saha V. 2003. Cryptic rearrangement involving MLL and AF10 occurring in utero. Leukemia 17: 1667-1669.
14. Jung R, Jacobs U, Krumbholz M, Langer T, Keller T, De Lorenzo P, Valsecchi MG, van der Velden VH, Moericke A, Stanulla M, Teigler-Schlegel A, Panzer-Gruemayer ER, van Dongen JJ, Schrappe M, den Boer ML, Pieters R, Rascher W, Metzler M. 2010. Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment. Leukemia 24: 903-907.
15. Kolomietz E, Meyn MS, Pandita A, Squire JA. 2002. The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes Cancer 35: 97-112.
16. Lee HJ, Thompson JE, Wang ES, Wetzler M. 2011. Philadelphia chromosome-positive acute lymphoblastic leukemia: Current treatment and future perspectives. Cancer 117: 1583-1594.
17. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P. 2010. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11: 1029-1035.
18. Mattarucchi E, Guerini V, Rambaldi A, Campiotti L, Venco A, Pasquali F, Lo Curto F, Porta G. 2008. Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. Genes Chromosomes Cancer 47: 625-632.
19. Melo JV. 1996. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88: 2375-2384.
20. Metzler M, Brehm U, Langer T, Viehmann S, Borkhardt A, Stanulla M, Schrappe M, Harbott J, Beck JD, Rascher W, Repp R. 2004. Asymmetric multiplex-polymerase chain reaction-A high throughput method for detection and sequencing genomic fusion sites in t(4;11). Br J Haematol 124: 47-54.
21. Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, Plantaz D, Bertrand Y, Bordigoni P, Guilhot F. 2005. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 116: 140-143.
22. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Ades L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NC, Chomienne C, Solomon E, Fenaux P, Grimwade D. 2005. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 352: 1529-1538.
23. Rassool FV. 2003. DNA double strand breaks (DSB) and non-homologous end joining (NHEJ) pathways in human leukemia. Cancer Lett 193: 1-9.
24. Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Muller MC, Hasford J, Heimpel H, Hehlmann R. 2009. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23: 602-604.
25. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP. 2010. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24: 1719-1724.
26. Schmid H, Jaeger BA, Lohse J, Suttorp M. 2009. Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 94: 1177-1179.
27. Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, Sobrinho-Simoes MA, Kreil S, Ward D, Hidalgo-Curtis C, Melo JV, Wiemels J, Nadel B, Cross NC, Grand FH. 2010. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia 24: 1742-1750.
28. Segal MR, Wiemels JL. 2002. Clustering of translocation breakpoints. J Am Stat Assoc 97: 66-76.
29. Sheather SJ, Jones MC. 1991. A reliable data-based bandwidth selection method for kernel density estimation. J R Statist Soc 53: 683-690.
30. Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, Watanabe A, Hotta N, Ito M, Kurosawa H, Kato K, Tsurusawa M, Horibe K, Shimada H. 2011. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 159: 676-681.
31. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR. 2000. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95: 738-743.
32. Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. 2010. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 116: 1329-1335.
33. Suttorp M, Millot F. 2010. Treatment of pediatric chronic myeloid leukemia in the year 2010: Use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program 2010: 368-376.
34. Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. 2008. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 135: 1130-1142.
35. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A. 1999. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 13: 1901-1928.
36. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. 2009. Chronic myeloid leukemia (CML) with P190 BCR-ABL: Analysis of characteristics, outcomes, and prognostic significance. Blood 114: 2232-2235.
37. von Goessel H, Jacobs U, Semper S, Krumbholz M, Langer T, Keller T, Schrauder A, van der Velden VH, van Dongen JJ, Harbott J, Panzer-Grumayer ER, Schrappe M, Rascher W, Metzler M. 2009. Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia. Leuk Res 33: 1082-1088.
38. Xiao Z, Greaves MF, Buffler P, Smith MT, Segal MR, Dicks BM, Wiencke JK, Wiemels JL. 2001. Molecular characterization of genomic AML1-ETO fusions in childhood leukemia. Leukemia 15: 1906-1913.
39. Zhang JG, Goldman JM, Cross NC. 1995. Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. Br J Haematol 90: 138-146.